Maraviroc Gel Prevents HIV-1 Vaginal Transmission
Author Information
Author(s): Neff C. Preston, Kurisu Theresa, Ndolo Thomas, Fox Kami, Akkina Ramesh
Primary Institution: Colorado State University
Hypothesis
Can a topical microbicide gel formulation of the CCR5 antagonist maraviroc prevent HIV-1 vaginal transmission in humanized mice?
Conclusion
The maraviroc gel fully protects humanized mice against vaginal HIV-1 challenge.
Supporting Evidence
- Maraviroc gel treated mice were fully protected against vaginal HIV-1 challenge.
- Placebo gel treated mice all became infected by the fifth week post challenge.
- No evidence of infection was seen in maraviroc treated mice throughout the 16-week observation period.
Takeaway
A special gel made from a medicine called maraviroc can stop mice from getting HIV when it's put in their vagina before they are exposed to the virus.
Methodology
Female RAG-hu mice were treated with maraviroc gel or placebo gel before being challenged with HIV-1 vaginally, and their infection status was monitored.
Limitations
The study is limited to a small animal model and may not fully represent human responses.
Participant Demographics
Female RAG-hu mice were used in the study.
Statistical Information
P-Value
0.0006
Statistical Significance
p<0.0006
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website